Saturday, November 21 Live

Bend Hub

News, roads, weather and events for Bend and Central Oregon.

News News

Editorial: Oregon’s battle over prescription drug prices

Full text, courtesy of The Bulletin

One battlefront of healthcare affordability is Oregon’s Prescription Drug Affordability Board.

The board, created by the Legislature, does what its name says — tries to keep prescription drug prices under control.

The board was working Wednesday morning to finalize its recommendations to the Legislature about what steps to take next. Organizations such as PhRMA, the Pharmaceutical Research and Manufacturers of America, and Regence Blue Cross Blue Shield, were telling the board they didn’t like some of the direction where the board wants to go.

The board basically discussed four draft recommendations for Oregon legislators:

Continuity. When a person switches commercial health plans their prescriptions should basically go with them, the board says.

Expanded scope. The board wants the ability to look at broader practices, purchasing arrangements, patient access and more to give it added flexibility to evaluate prescription drugs costs and perhaps drive legislative changes.

Orphan drugs. Orphan drugs are used for treating rarer diseases and conditions. The board is seeking the ability to look at costs for orphan drugs when they are used for both treating the rarer diseases and conditions that they are specifically authorized for other diseases and conditions.

Pharmacy benefit managers. The board wants to do additional work to evaluate the practices of pharmacy benefit managers and how they impact drug pricing.

A representative from PhRMA testified before the board that it supported the board’s recommendation about continuity of care and looking at the transparency of pharmacy benefit managers. She expressed concern that the board does not have a clear definition of what affordability means and may expand its scope to an overly broad review of business practices. Similarly, a representative from Regence said it wanted the board to demonstrate progress on affordability before expanding the board’s scope.

Where was the voice of Oregon consumers in that debate on Wednesday? That was less clear. Lobbyists have the time, expertise and get paid to advocate for their industries. You can help balance that by sending in your comments to the board on those recommendations. You can read the draft report yourself buried in this document: tinyurl.com/ORdrugmeeting. There is information about how to send in comments here: tinyurl.com/ORdrugcomments.

Editorials reflect the views of The Bulletin’s editorial board, Editor Jody Lawrence-Turner, Editor Tim Trainor and Editorial Page Editor Richard Coe.

Original story at The Bulletin

More News news

Search the site · Map · Report a correction